Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAISE-KT: Semaglutide for Kidney Transplant Candidacy
NCT04741074Phase 3Terminated
- Sponsor
- Geisinger
- Start
- Jul 2021
- Primary completion
- Jan 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), obesity, sponsored by Geisinger. Started Jul 2021; status: terminated.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT04741074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04741074.